(BPT) – The third week of September is Mito Awareness Week, a time to recognize mitochondrial diseases. Mitochondrial diseases affect the mitochondria, the structures of the cells that are responsible ...
First published data from a multicenter retrospective chart review study to explore the safety and efficacy of pyrimidine nucleoside and/or nucleotide therapy in patients with thymidine kinase 2 ...
Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) could be just weeks away from having the first ...
What Is Kygevvi, and Why Does It Matter? Kygevvi is a new oral medicine for people with thymidine kinase 2 deficiency (TK2d), an extremely rare genetic condition affecting the muscles. The FDA has ...
Thymidine kinase 2 deficiency (TK2d) is a very rare genetic disease that causes muscle weakness, which can happen in different parts of your body. TK2d can sometimes be severe and affect your ability ...
Transmission electron microscope image of a thin section cut through an area of mammalian lung tissue. The high magnification image shows two mitochondria. People living with thymidine kinase 2 ...
UCB will contribute three presentations, including data on the disease course of thymidine kinase 2 deficiency (TK2d) in untreated patients and insights into caregiver impact These data emphasize ...
EMA committee recommends marketing approval for UCB’s Kygevvi to treat thymidine kinase 2 deficiency
EMA committee recommends marketing approval for UCB’s Kygevvi to treat thymidine kinase 2 deficiency: Brussels, Belgium Monday, February 2, 2026, 15:00 Hrs [IST] UCB, a global b ...
UCB has announced that its developmental treatment DoxTM, a combination of doxecitine and doxribtimine, has been granted Promising Innovative Medicine (PIM) designation by the Medicines and Healthcare ...
A groundbreaking FDA approval offers the first-ever treatment for ultra-rare Thymidine Kinase 2 Deficiency (TK2d). KYGEVVI, a combination therapy, provides hope for children and adults by addressing ...
New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- New York, Monday, November 3, 2025 - The Muscular Dystrophy Association (MDA) marks another milestone today in our legacy of progress with the FDA approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results